Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Lung04: BL-B01D1 + osimertinib versus osimertinib in first-line EGFR-mutant advanced NSCLC
CTR20250537Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Feb 2025; status: active.
02
Drugs
izalontamab brengitecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250537.